An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay

Annals of Pharmacotherapy

Volumn 44, Issue 9, 2010, Pages 1504-1507

  Bonnici, André ^a,b   Ruiner, Carola Ellen ^a   St Laurent, Lyne ^a   Hornstein, David ^c,d  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Enteral nutrition; Interaction; Levodopa; Neuroleptic malignant like syndrome; Parkinson's disease

Indexed keywords

BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; CREATINE KINASE; CREATININE; ENTACAPONE; HEPARIN; INFUSION FLUID; NITROGEN; NORADRENALIN; NOVASOURCE RENAL; OSMOLITE; PRAMIPEXOLE; RESOURCE DIABETIC; TAP WATER; TIMENTIN; UNCLASSIFIED DRUG; UREA;

ACUTE KIDNEY FAILURE; ADULT; ALERTNESS; ARTICLE; ARTIFICIAL VENTILATION; BACILLUS CEREUS; BLOOD PRESSURE; BODY WEIGHT; BRADYKINESIA; CASE REPORT; CERVICAL SPINE FRACTURE; COUGHING; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DETERIORATION; DIET; ENTERIC FEEDING; EXTUBATION; FEVER; GLASGOW COMA SCALE; GLYCEMIC CONTROL; HEMODYNAMIC MONITORING; HOSPITAL ADMISSION; HUMAN; HYDRATION; INTENSIVE CARE UNIT; INTUBATION; KIDNEY FUNCTION; LEUKOCYTE; LEUKOCYTE COUNT; LEUKOCYTOSIS; LUMBAR SPINE; LUNG CONTUSION; MALE; MENTAL HEALTH; MORBID OBESITY; MULTIPLE TRAUMA; NASOGASTRIC TUBE; NEUROLEPTIC MALIGNANT SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN FRACTURE; ORIENTATION; PARKINSON DISEASE; PNEUMONIA; POSTOPERATIVE ANALGESIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN INTAKE; RETREATMENT; RIB FRACTURE; SPINE FRACTURE; SPUTUM CULTURE; STIMULUS; THORAX RADIOGRAPHY; TRAFFIC ACCIDENT; UPPER RESPIRATORY TRACT; UREA NITROGEN BLOOD LEVEL; VENA CAVA FILTER; WAKEFULNESS; YEAST;

ANTIPARKINSON AGENTS; CARBIDOPA; DRUG THERAPY, COMBINATION; ENTERAL NUTRITION; FOOD-DRUG INTERACTIONS; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; LEVODOPA; MALE; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSON DISEASE;

EID: 77956245193     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P242     Document Type: Article

References (15)

1. Mizuno Y, Takubo H, Mizuta E, Kuno S. Malignant syndrome in Parkinson's disease: concept and review of the literature. Parkinsonism Relat Disord 2003;9(suppl 1):S3-9.
2. Gibb WR, Griffith DN. Levodopa withdrawal syndrome identical to neuroleptic malignant syndrome. Postgrad Med J 1986;62:59-60. (Pubitemid 16163923)
3. Toru M, Matsuda O, Makiguc K, Sugano K. Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs. J Nerv Ment Dis 1981;169:324-7.
4. Fujitake J, Kuno S, Nishitani H. [Neuroleptic malignant syndrome-like state in eight patients with parkinsonism] Japanese. Rinsho Shinkeigaku 1984;24:371-8.
5. Thomas A, Onofrj M. Akinetic crisis, acute akinesia, neuroleptic malignant-like syndrome, Parkinsonism-hyperpyrexia syndrome, and malignant syndrome are the same entity and are often independent of treatment withdrawal. Mov Disord 2005;20:1671; author reply 1671-2.
6. Karstaedt PJ, Pincus JH. Protein redistribution diet remains effective in patients with fluctuating parkinsonism. Arch Neurol 1992;49:149-51.
7. Pincus JH, Barry KM. Plasma levels of amino acids correlate with motor fluctuations in parkinsonism. Arch Neurol 1987;44:1006-9.
8. Gordon PH, Frucht SJ. Neuroleptic malignant syndrome in advanced Parkinson's disease. Mov Disord 2001;16:960-2.
9. Cooper MK, Brock DG, McDaniel CM. Interaction between levodopa and enteral nutrition. Ann Pharmacother 2008;42:439-42. DOI 10.1345/aph.1K450
10. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45. (Pubitemid 12149145)
11. Horn JR, Hansten PD, Chan L-N. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41:674-80. DOI 10.1345/aph.1H423
12. Yamawaki Y, Ogawa N. [Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) with disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease] Japanese. Rinsho Shinkeigaku 1991;31:62-7.
13. Olmsted TR. Neuroleptic malignant syndrome: guidelines for treatment and reinstitution of neuroleptics. South Med J 1988;81:888-91.
14. Martindale RG, McClave SA, Vanek VW, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition: Executive Summary. Crit Care Med 2009; 37:1757-61.
15. Reichmann H, Herting B, Muller A, Sommer U. Switching and combining dopamine agonists. J Neural Transm 2003;110:1393-400.